Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04682301
Other study ID # RG1121165
Secondary ID NCI-2020-0839310
Status Completed
Phase
First received
Last updated
Start date February 5, 2021
Est. completion date March 14, 2023

Study information

Verified date May 2024
Source Fred Hutchinson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study tailors a shared decision making intervention for lung cancer screening in persons living with human immunodeficiency virus (HIV). Information collected in this study may help doctors better understand how to perform lung cancer screening in persons living with HIV, so as to enhance shared decision making in persons living with HIV.


Description:

OUTLINE: AIM I: Participants attend a focus group over 1-1.5 hours providing feedback on refining potential methods of shared decision making (SDM). AIM II: Participants receive the SDM intervention developed in Aim I and provide feedback. Participants may attend a telephone interview over 45 minutes 1 month later.


Recruitment information / eligibility

Status Completed
Enrollment 102
Est. completion date March 14, 2023
Est. primary completion date March 14, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - AIM I: Patients with human immunodeficiency virus (PWH) enrolled in the local UW HIV cohort and primary providers at Madison Clinic and other Seattle-based clinics serving PWH - AIM I: Using proposed United States Preventive Services Task Force (USPSTF) guidelines, participants enrolled in the registry who are current or former smokers, report >= 20 pack-years smoking history, and >= 50 years old (n=165) will be eligible for recruitment - AIM I: Clinicians (medical doctors, physicians assistants and nurse practitioners) who provide primary care for PWH (n=48) will be eligible - AIM II: PWH who are eligible for lung cancer screening (LCS) based on proposed USPSTF criteria Exclusion Criteria: - Those found to be ineligible for LCS on coordinator review - Are non-English speaking or have cognitive dysfunction that would prevent participation in SDM

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioral Intervention
Receive SDM intervention
Other:
Discussion (focus group)
Attend focus group
Discussion (feedback on SDM)
Provide feedback on SDM
Interview
Attend a telephone interview
Survey Administration
Ancillary studies

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Focus Group Analysis (Aim I) All focus groups will be recorded and transcribed. Will use a framework analysis approach which combines both inductive and deductive methods where generated themes are mapped onto an implementation framework, specifically the Tailored Implementation of Chronic Diseases (TICD) checklist. Codes will then be analyzed through a constant comparison method to determine key themes. Will analyze all focus groups in real time to make iterative changes to the focus group guide based on feedback and refining potential methods of shared decision making (SDM). Pre-/post-SDM survey data will be collected via tablet, with a paper option if desired.
Effectively, number of participants who complete focus group participation for analysis.
During focus participation, an average of 1-1.5 hours
Primary Improvement in Lung Cancer Screening Knowledge (LKS), According to Pre- vs. Post-intervention Scores (Aim II) The primary outcome was change in knowledge of LCS after using the tailored decision aid. We used two validated measures of LCS knowledge, the LCS-12 and LKS-7, to evaluate knowledge of risks, benefits, and characteristics of LCS. The LCS-12 includes twelve multiple-choice questions which assess knowledge of lung cancer risk, characteristics of LCS, and benefits and harms of LCS. The LKS-7 uses seven questions assessing understanding of the harms and benefits LCS, incidental findings, and the screening process. Our enrollment target was 40-50 patients to achieve greater than 90% power to observe a difference similar to a prior study in pre- and post-SDM knowledge of screening harms (69% to 93%). Minimum score of 0 for LCS-12 and LKS-7, indicating no improvement from pre- to post-intervention assessment on LCS knowledge; maximum score of 12 for LCS-12 and 7 for LKS-7. Higher score represents better outcome, or greater improvement from pre- to post-intervention on measures of LKS. During shared decision-making participation, an average of 1 hour
Primary Decision of Cancer Screening (DCS) (Aim II) The Decision of cancer screening (DCS) was used to evaluate participants' decisional conflict after SDM visits. The ten-item lower literacy DCS was selected with possible scores ranging from 0 (minimum; no decisional conflict) to 100 (maximum; extremely high decisional conflict), with possible sub-scores for resulting feelings of uncertainty, feeling informed, clarity of values regarding risks and benefits, and feeling supported. Each question has options for yes (0), unsure (2), and no (4); answers are summed, divided by ten, then multiplied by 25 to provide the overall DCS. Lower scores represent a better outcome, or no/low decisional conflict. During shared decision-making participation, an average of 1 hour
Primary Acceptability of Intervention Measure (AIM) (Aim II) The AIM was used to evaluate the acceptability of the intervention for participants. The AIM is a four-item measure to assess the acceptability of a given intervention, in this case the decision aid, producing responses on a scale from 1 (completely disagree) to 5 (completely agree) and higher scores indicating greater acceptability.
The score is calculated by taking the mean of the four responses. Scores range from 1-5.
During shared decision-making participation, an average of 1 hour
Primary Fidelity (Aim II) Fidelity summarized as median percent of a 10-item checklist completed. Higher percentages represented a better outcome, or greater fidelity to the intervention/completion of items throughout intervention. Minimum percentage of completion is 0; maximum percentage of completion is 100. During shared decision-making participation, an average of 1 hour
See also
  Status Clinical Trial Phase
Recruiting NCT04931017 - Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer Phase 2
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Not yet recruiting NCT06038526 - Evaluation of Canakinumab in High-Risk Former-Smokers Phase 2
Terminated NCT02856581 - Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes Phase 3
Completed NCT04922697 - Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study N/A
Recruiting NCT04644952 - The Rise in Robotic Atypical Segmentectomies
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05407168 - Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool N/A
Completed NCT04267874 - Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study Early Phase 1
Recruiting NCT02408861 - Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Recruiting NCT03709953 - Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma Phase 2
Active, not recruiting NCT03267524 - Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT02237183 - Iloprost in Preventing Lung Cancer in Former Smokers Phase 1
Recruiting NCT04783168 - Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study N/A
Completed NCT04635761 - Awareness, Information, and Resources for Lung Cancer Screening Program for Community-Partnered Lung Cancer Screening N/A
Recruiting NCT06445192 - Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial N/A
Active, not recruiting NCT03164486 - First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide Early Phase 1
Recruiting NCT05802186 - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study N/A
Active, not recruiting NCT01696968 - Screening for Lung Cancer in Older Patients (PLCO Screening Trial) N/A